REFERENCES
- Atkins P. J., Barker N. P., Mathisen D. Inhalation drug delivery systems. Pharmaceutical Inhalation Aerosol Technology, A. J. Hickey. Marcel Dekker, New York 1992; 155–185
- June D. S., Schultz R. K., Miller N. C. A conceptual model for the development of pressurized metered-dose hydrofluoroalkane-based inhalation aerosols. Pharm. Technol. 1994; 18: 40–52
- Ewing C., Shadded D., Gelotte K. Dose delivery characterization of a solution-based metered-dose inhaler formulation. Pharm. Res. 1997; 14: S–137
- Phillips E. Crystal growth-formulation dependence and early detection. J. Biopharm. Sci. 1992; 3: 11
- Dalby R. N., Phillips E. M., Byron P. R. Determination of drug solubility in aerosol propellants. Pharm. Res. 1991; 8: 1206–1209
- Mithani S. D., Bakatselou V., TenHoor C. N., Dressman J. B. Estimation of the increase in solubility of drugs as function of bile salt concentration. Pharm. Res. 1996; 13: 163–167
- Caron J. C., Shroot B. Determination of partition coefficients of glucocorticosteroids by high-performance liquid chromatography. J. Pharm. Sci. 1984; 73: 1703–1706
- Martin A. Physical Pharmacy. Lea and Febiger, Philadelphia 1993
- Byron P., Blondino F. Metered dose inhaler formulations which included the ozone-friendly propellant HFC 134A and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent. U.S. Patent 5,492,688, February 1996
- Byron P., Blondino F. Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant. U.S. Patent 5,508,023, April 1996